Abstract
Stability Indicating Method for the Determination of Mefenamic Acid in Pharmaceutical Formulations by HPLCBhagyashree R. Dhumal, Kishore P. Bhusari, Madhukar R. Tajne, Mahavir H. Ghante, Nishant S. Jain
Highlights
Mefenamic acid (MFA) is a well-known as nonsteroidal anti-inflammatory drug (Figure 1) has low aqueous solubility, so its absorption in gastrointestinal tract (GIT) is limited by its dissolution, has a low bioavailability after oral administration (Merck Index, 1996)
Mefenamic acid (MFA) and Nicotinamide (NIC) cocrystal formation in co-milling treatment was investigated by x-ray powder diffractometry (XRPD)
The knowledge of kinetic formation is useful to investigate the pathway of cocrystal formation, especially in the drugs such as MFA that the polymorphic transformation caused by milling process
Summary
Mefenamic acid (MFA) is a well-known as nonsteroidal anti-inflammatory drug (Figure 1) has low aqueous solubility, so its absorption in gastrointestinal tract (GIT) is limited by its dissolution, has a low bioavailability after oral administration (Merck Index, 1996). The polymorphic transformation of MFA I to MFA II to be formed by co-milling (Kato et al, 2014), cryomilling process (Kang et al, 2015), heating crystals of MFA I above the transition temperature (165-175°C) and by rapid cooling of a supersaturated of MFA I in DMF (Romero et al, 1999 ; Surov et al, 2009) Fabian et al (2011) has been studied cocrystal formation of five fenamic acid drugs, including MFA with NIC based on supramolecular heterosynthon of both. The knowledge of kinetic formation is useful to investigate the pathway of cocrystal formation, especially in the drugs such as MFA that the polymorphic transformation caused by milling process. While for those who are not involved in the cocrystal exploration, is to anticipate the possibility of the formation of cocrystal for pharmaceutical processes, such as grinding, especially for active ingredients that susceptible to the polymorph transformation by grinding process
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
